SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reports of Nvidias board weighing Jensen Huangs removal amid allegations involving a company executive and a suspected Chinese intelligence link have put leadership, governance, and national-security risks at the center of discussion. Traders are split between fearing a CEO transition and further volatility and arguing the allegations are unproven and Nvidias AI business remains strong.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor shares rallied after a Jones Trading upgrade and managements confidence in deramiocel, ahead of the FDAs Nov. 22 decision on the Duchenne muscular dystrophy treatment. Traders are split over approval versus rejection risk, while claims of an FDA leak and a short squeeze remain speculation.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment includes To-Home businesses, which include Ele.me, local services and delivery platforms, and Taoxianda, and To-Destination segment businesses, which include Amap, the provider of mobile digital maps, navigation and real-time traffic information, and restaurant and local services guide platforms. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solutions. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is drawing attention amid speculation that alleged NvidiaMegaspeed chip-diversion and espionage links could spill over to the company and bring tighter U.S. export controls, weighing on sentiment toward Chinese AI stocks. Traders disagree over whether Alibaba has a meaningful connection to the allegations, while some see its T-Head chip unit and AI-cloud business as potential positives.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels positive Phase 3 prostate-cancer results and new SITC immune-response and viral-clearance findings are fueling attention ahead of the planned BLA for aglatimagene (CAN-2409). Bulls view the data as supportive of the filing, while skeptics focus on submission timing, manufacturing readiness, funding and dilution risks amid weak trading.

GraniteShares ETF Trust - GraniteShares 2x Long NVDA Daily ETF

GraniteShares 2x Long NVDA Daily ETF

Headlines and speculation about Nvidias board potentially ousting CEO Jensen Huang amid a personal-conduct controversy have fueled a sharp NVDA-linked selloff and rebound in NVDL. Traders are divided between buying the dip and warning that the ETFs 2x daily leverage can magnify further volatility; claims about Huangs departure remain unconfirmed in the discussion.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos upcoming quarterly report is the dominant focus, with traders watching whether AI infrastructure orders translate into sustained revenue and cash generation. Bullish traders anticipate strong results and guidance, while skeptics question whether orders reflect durable demand or spending pulled forward and flag margin and inventory risks.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is drawing attention amid a prolonged selloff in Chinese tech stocks, with traders pointing to weak demand for China-listed equities and concerns about Baidus ad business, AI monetization and lack of clear catalysts. The community is split between buyers calling the shares undervalued and bears warning they could remain a value trap; hopes for a Kunlunxin IPO or a China-market rebound remain speculative.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention ahead of its quarterly results after CoreWeaves strong report boosted the AI-cloud sector, with traders hoping Nebius will confirm robust demand. Bulls anticipate another earnings-driven rally, while skeptics say the run-up may have priced in strong results and question how the company will fund its expansion; Nvidia-related headlines are adding volatility.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius latest quarterly report is driving attention: strong revenue growth and a higher outlook were offset by an EPS miss and weaker EBITDA, and shares sold off despite the upbeat top-line results. Bulls view the decline as an overreaction and emphasize growth and improving margins, while skeptics focus on continued losses, cash burn, and dilution risk.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JDs persistent weakness alongside Chinese equities is fueling debate over whether its low valuation, cash reserves and buybacks outweigh China-related sentiment, competition and soft consumer demand; bulls also cite Michael Burrys added position as support for the value case, while skeptics question whether it can reverse the slide. Traders are watching upcoming earnings and the Ceconomy deal as possible catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Skye Bioscience (SKYE) Shares Rise 6% After Hours: Here's What's Driving The Move

Skye Bioscience shares rise 6% after hours on a $22M equity purchase agreement and warrant issuance.read more...

Why HIVE Digital Technologies Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket

HIVE Digital Technologies Ltd (NASDAQ: HIVE) rose in pre-market trading due to its subsidiary's new agreement. Other gainers include IP Strategy Holdings, INVO Fertility, My Size, Trugolf Holdings, Expion360, Skye Bioscience, Julong Holding, FIEE Inc, and Keel Infrastructure. Losers include...

Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE

Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group...

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit...

SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit

SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud...

Class Action Filed Against Skye Bioscience, Inc. (SKYE) - January 16, 2026 Deadline to Join - Contact The Gross Law Firm

Class Action Filed Against Skye Bioscience, Inc. (SKYE) - January 16, 2026 Deadline to Join - Contact The Gross Law Firm Class Action Filed Against Skye Bioscience, Inc. (SKYE) - January 16, 2026...

SKYE Deadline: Rosen Law Firm Urges Skye Bioscience, Inc. (NASDAQ: SKYE) Stockholders to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025. Skye is a clinical stage...

Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before January 16, 2026 to Discuss Your Rights - SKYE

Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before January 16, 2026 to Discuss Your Rights - SKYE Skye Bioscience, Inc. Securities Fraud Class...

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK...

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 6, 2026 NEW YORK...

Reported GAAP EPS of -$0.31 up 29.55% YoY

Skye Bioscience faces substantial going concern risks, potential Nasdaq delisting, and the complete termination of its lead clinical program, nimacimab, following unfavorable trial results and a strategic business review.

Skye Bioscience has entered into a strategic acquisition agreement with Redx Pharma Limited, supported by a $103.9 million financing plan, while previously demonstrating potential clinical efficacy for its combination therapy.

Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the business of research and development activities related to developing medicine for obesity and metabolic diseases. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.

Skye Bioscience Inc

Why Did Skye Bioscience Stock Plummet A Whopping 60% Today?

Equity

Neutral Sentiment

Shares of Skye Bioscience, Inc. (SKYE) dived 60% in the pre-market session on Monday after the company said that its Nimacimab alone did not cause weight loss as compared to placebo in a mid-stage trial.Preliminary analysis suggested that 200 mg of Nimacimab as a subcutaneous weekly dose was suboptimal as a monotherapy, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.skyebioscience.com/news-releases/detail/244/skye-bioscience-reports-topline-cbeyond-phase-2a-data-from-nimacimab-monotherapy-and-combination-clinical-trial">said</a>. The data, however, support the evaluation of higher dosing, the company said.Further, Nimacimab in combination with Novo Nordisk’s Semaglutide demonstrated a clinically meaningful magnitude of weight loss compared to Semaglutide alone, the company said. The positive observation supports further studies where Nimacimab is used with other therapies, it added.The drug alone and in combination demonstrated a clean safety profile, with no added gastrointestinal adverse events and no increases in neuropsychiatric adverse events reported resulting from treatment with Nimacimab, Skye said. Overall, the study, which enrolled 136 adults with overweight or obesity, had a discontinuation rate of 27%. Notably, 3.7% of the discontinuations were due to adverse events, with the placebo group contributing 60% of these discontinuations, according to the company.“With our preclinical data, toxicology safety margins, and PK modeling, we believe we have a path to support higher dosing, and we are evaluating the next stage of development to optimize dosing in potential future clinical trials," said Puneet Arora, Chief Medical Officer of Skye Bioscience. The company is now evaluating the data to determine the next steps for the development of the drug.SKYE stock is up 68% this year and by about 24% over the past 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

The company stated that its investigational drug alone did not cause weight loss compared to the placebo in a mid-stage trial. 

iShares Micro-Cap ETF

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$SKYE I think Puneet is done here. They have new plans for the SKYE. A new ceo - a new ticker - a new scam.  Wash rinse repeat……

Willy brown

$SKYE 😮 can’t beleive everyone adding with such bullish price movement… this is disgusting.🤢

Yahtzee27

$SKYE … this will go down in history as the worst stock I’ve ever invested in in my life. I believe I’ve been holding this for almost 10 years. I have gone through multiple name changes and multiple reverse splits. Everyone at this company should be in prison.

#Crypto4Life

$SKYE … I have been scammed by this company for the past 10 years. Multiple name changes and countless reverse splits. Everyone at this company should be in prison.

$SKYE Our ceø PD belongs in the Hall of Fame for pøs ceø's of the 2Ist century. Congrats to Mr D!!!

ketö tıtr

$SKYE Came back to check in on this trash heap...back under $1. LOL.  Actually surprised it took this long.

Michael

$SKYE shorts are trapped, they’re trying to churn up volume but it’s not enough. SEC filings are coming and this will go parabolic.

Jack Guthridge

Short sellers are ruining american small caps and driving companies into bankruptcy!!        
        
FMFC has barely 800 watchers on Stocktwits and has been shorted down to only 1.5 million market cap. You could literally buy the ENTIRE company!        
        
Webull data stating that FMFC has only 492k shares outstanding and 243k shares float.         
        
 Watch FMFC here. Making a move 🚀 💎 👀 
 
$SKYE $CISS ~~~

Feed

News

Sentiment

Earnings

Fundamentals

Info

SKYE Skye Bioscience Inc

Fundamentals

Latest SKYE News